Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics. Appropriate care is advised when prescribing ziprasidone for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder, and close supervision of high-risk patients should accompany drug therapy.

GEODON Capsules should be administered at an initial daily dose of 40 mg twice daily with food. The patient should be carefully monitored, since recurrences of NMS have been reported.

Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. These studies indicate that the reduction reaction is mediated primarily by chemical reduction by glutathione as well as by enzymatic reduction by aldehyde oxidase and the subsequent methylation is mediated by thiol methyltransferase. If sympathomimetic agents are used for vascular support, epinephrine and dopamine should not be used, since beta stimulation combined with antagonism associated with ziprasidone may worsen hypotension. Ziprasidone was shown to increase time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m basis). Exposure increases in a dose--related manner and following three days of intramuscular dosing, little accumulation is observed. Low serum potassium and magnesium should be replaced before proceeding with treatment. Specialties Psychiatric posted Jun 8, 2013. Ziprasidone dosed adjunctively to lithium in a maintenance trial of bipolar patients did not affect mean therapeutic lithium levels. GEODON for Injection should be stored below 25°C (in dry form). As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with impaired renal function As ziprasidone is cleared substantially by the liver, the presence of hepatic impairment would be expected to increase the AUC of ziprasidone; a multiple-dose study at 20 mg twice daily for 5 days in subjects (n=13) with clinically significant (Childs-Pugh Class A and B) cirrhosis revealed an increase in AUC and 34% in Childs-Pugh Class A and B, respectively, compared to a matched control group (n=14). A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Syncope was reported in 0.6% of the patients treated with ziprasidone. Each mL of reconstituted solution contains 20 mg ziprasidone. The occurrence of rash was related to dose of ziprasidone, although the finding might also be explained by the longer exposure time in the higher dose patients. Pooled data from short-term, placebo-controlled studies in schizophrenia and bipolar disorder are presented in Tables 1-4. Discontinue ziprasidone if severe cutaneous adverse םוקימב םייוניש אלו יתוהמ ןכות קר ןמסל שי .הנוש עבצב .טסקטה הפורתב שומישה ךלהמב הלולע רישכתל תרחואמ הבוגת עיפוהל היליפוניזואא םע הבוגת היורקה רישכתל םיימטסיס םינימסתויושע ) ,החירפ :לולכל םי .תולדגומ הפמיל תוטולבו םוח תויהל םיתיעל הלולע וז הבוגת עידוהל שי ןכ לע ,םייח תנכסמ ןיחבמ ךנה םא תידיימ אפורל .הינימסתב הפורתב שומישה ךלהמב עיפוהל הלולע רישכתל תרחואמ הבוגת םע הבוגת היורקה רישכתל םיימטסיס םינימסתו היליפוניזואא עיפוהל הלולעה תפסונ הרומח הבוגת תארקנ לופיטה ךלהמב סנביטס תנומסת תויחופלש םע החירפ :לולכל םילולע הינימסתש םוח ,רועה לש ףוליק ,הפב םיביכ םג ונכתי .רועה לע תודוקנ תעפוהו שי ןכ לע ,םייח ןיחבמ ךנה םא תידיימ אפורל עידוהל הינימסתביש אלו יתוהמ ןכות קר ןמסל שי .הנוש עבצב םוקימב םייונ .טסקטה

In many cases this would lead to the conclusion that other drugs should be tried first. After intramuscular administration of single doses, peak serum concentrations typically occur at approximately 60 minutes post-dose or earlier and the mean half-life (T) ranges from two to five hours. It is recommended that women receiving ziprasidone should not The safety and effectiveness of ziprasidone in pediatric patients have not been established.